[Genetic Counselor]

Peutz-Jeghers syndrome follows an autosomal dominant pattern of inheritance, meaning a change in just one of the two copies of the STK11 gene is sufficient to cause the condition.

• The majority of people diagnosed with Peutz-Jeghers syndrome, roughly sixty to seventy-eight percent in large studies, have an affected parent.
• A meaningful proportion, estimated at somewhere between seventeen and forty-five percent depending on the study, appear to be the only affected person in their family. In some of these individuals the genetic change arose new, described as a de novo change, while in others a parent carries the change in only some of their cells or reproductive cells, a situation called mosaicism, which can be difficult to detect on routine testing.
• Everyone who has been found to carry a disease-causing change in STK11 has gone on to show at least some clinical feature of the condition, meaning penetrance is considered complete, although the specific features and their severity vary widely from person to person, even within the same family.
• If a parent is confirmed to be affected or to carry the family’s specific genetic change, each of that person’s children, including future children, has a fifty percent chance of inheriting the same change.
• If neither parent shows clinical features and the genetic change cannot be found in either parent’s blood sample, the chance of the condition recurring in future children is still slightly higher than in the general population, because of the possibility of undetected parental mosaicism.

Because an apparently negative family history cannot be fully relied upon without proper clinical and genetic evaluation of both parents, referral for genetic counseling is strongly recommended for accurate, family-specific risk assessment and for discussion of reproductive options such as prenatal testing.

[Genetic Counselor]

Peutz-Jeghers syndrome affects the digestive tract and skin most prominently, though its cancer risk extends to several other organs. Doctors look for a specific combination of clinical findings to establish the diagnosis.

• Gastrointestinal polyps: a distinctive type of polyp, called a hamartomatous polyp, occurs most often in the small intestine, particularly the segment nearest the stomach, but can also appear in the stomach, large bowel, and occasionally outside the digestive tract altogether. These polyps can cause chronic bleeding, anemia, and, especially in children and young adults, a serious folding-in of the bowel called intussusception, which may require emergency surgery.
• Skin and mucous membrane pigmentation: dark blue to dark brown spots typically appear in early childhood around the mouth, eyes, and nostrils, inside the cheeks, on the fingers, and around the anus. These spots often fade during the teenage years and adulthood, so their presence is most useful for diagnosis in children.
• Family history: any number of the characteristic polyps or the characteristic skin spots occurring in a person with a close relative who has confirmed Peutz-Jeghers syndrome supports the diagnosis.

A clinical diagnosis can be made when a person has two or more of the characteristic polyps confirmed on tissue examination, any number of these polyps together with a family history of the condition, characteristic skin spots together with a family history, or both the polyps and the skin spots together. Because the skin spots may be subtle and the polyps may cause no symptoms for years, genetic testing of the STK11 gene, usually starting with sequencing followed by testing for larger deletions or duplications if needed, is used to confirm the diagnosis and to allow testing of at-risk relatives.

[Genetic Counselor]

Peutz-Jeghers syndrome is an inherited condition marked by three main features: growths called polyps in the gastrointestinal tract, distinctive dark spots on the skin and inside the mouth, and an increased lifetime risk of several cancers. The severity and combination of features can differ considerably even among members of the same family, a pattern doctors call variable expressivity; some relatives who carry the same genetic change may have only a few skin spots, while others develop extensive polyps requiring repeated procedures.

The condition is caused by changes, known as pathogenic variants, in a single gene called STK11, located on chromosome 19. STK11 provides instructions for a protein that acts as a tumor suppressor, meaning it normally helps control how and when cells divide, and also plays roles in programmed cell death, cell shape and organization, and how cells use energy. When one of the two copies of STK11 that a person carries is altered, this control is disrupted, allowing the characteristic polyps to form and contributing to the elevated cancer risk seen in this condition.

More than three hundred different disease-causing changes have been identified in STK11 to date, ranging from small alterations affecting a single building block of the protein to loss of the entire gene.
A small number of people who clearly show the clinical features of Peutz-Jeghers syndrome do not have a detectable change in STK11 on standard testing. In some of these individuals, the genetic change may be present in only a portion of the body’s cells, a situation called mosaicism, which can be missed by testing a routine blood sample. Testing an alternate tissue source, such as cells from the inside of the cheek, is sometimes considered in this situation.

[Genetic Counselor]

At the present, the best treatment presently available is symptomatic management.
There is no complete cure for Duchenne muscular dystrophy, but coordinated, multidisciplinary care meaningfully extends both survival and quality of life, and the treatment landscape has changed substantially over the past decade.
• Corticosteroids, typically prednisone or deflazacort, are the cornerstone of treatment once a plateau or decline in motor skills is noticed, usually between ages four and eight. They measurably slow the loss of muscle strength and function, delay loss of independent walking, and are often continued after walking is lost to help preserve arm strength and slow the progression of scoliosis and breathing decline, though they carry real trade-offs including weight gain, slowed growth, and increased fracture risk that require ongoing monitoring.
• Exon-skipping therapies are a newer class of genotype-specific treatments that use synthetic molecules to restore the disrupted reading frame in certain genetic changes, allowing the body to produce a shortened but partially functional dystrophin protein. Several have received United States regulatory approval, each applicable only to individuals whose specific genetic change is amenable to skipping a particular exon, together covering roughly thirty percent of individuals with DMD.
• Cardiac medications, including ACE inhibitors, angiotensin receptor blockers, and beta blockers, are used, often starting before symptoms appear, to protect and support heart function, since heart involvement affects nearly everyone with DMD by adulthood.
• Gene transfer therapy, using viral vectors to deliver a shortened, functional version of the dystrophin gene, has moved from clinical trials toward wider use in recent years and is applicable regardless of a person’s specific genetic change, though it cannot restore full-length dystrophin and its long-term durability is still being studied.
• Orthopaedic and rehabilitative care includes physical therapy to maintain mobility and prevent joint contractures, bracing or spinal surgery for scoliosis, and attention to bone health, including vitamin D and calcium optimization, given the fracture risk associated with reduced mobility and corticosteroid use.
• Respiratory support, including assisted cough techniques and, over time, non-invasive or invasive ventilation, becomes increasingly important as breathing muscles weaken, particularly after independent walking is lost.
Additional supportive measures include nutritional assessment, annual influenza and pneumococcal vaccination, and specific anesthesia precautions, since individuals with dystrophinopathies can react severely to certain anesthetic agents. There are treatment trials available in India, you can refer [https://genetidoc.com/rarediseaseforum/forums/forum/genetic-trials-registry/indian-trials/duchenne-muscular-dystrophy-dmd/] for more information on them

[Genetic Counselor]

The natural course of Duchenne muscular dystrophy is one of steady, progressive muscle weakness, with most individuals losing the ability to walk independently by around age twelve, though the age at which this happens, and the pace of decline afterward, vary somewhat from person to person and can be meaningfully slowed by corticosteroid treatment. Historically, survival beyond the third decade of life was unusual, but with modern multidisciplinary care, particularly proactive respiratory and cardiac management, median survival has extended into the late twenties and beyond, with some individuals living well into their thirties or longer. Respiratory failure and progressive heart muscle disease remain the most common causes of death.

Because the disease affects several body systems and changes in character over time, from early childhood through the teenage and young adult years, ongoing surveillance across specialties is recommended for life.
• Cardiac: a full cardiac evaluation, including an electrocardiogram and an imaging study such as echocardiography, is recommended at least every two years starting at diagnosis, moving to annual evaluation from around age ten or with the onset of any cardiac symptoms, and every six months if reduced heart function is found.
• Pulmonary: baseline lung function testing is obtained before an individual becomes wheelchair dependent, typically around age nine or ten, with evaluation by a lung specialist at least twice yearly once they are using a wheelchair, once lung capacity falls below eighty percent of the expected value, or by age twelve, whichever comes first.
• Orthopedic: regular monitoring for scoliosis and joint contractures, with bracing or surgical referral as needed.
• Bone health: periodic blood and urine testing, along with bone density scanning, particularly for those on long-term corticosteroid treatment or with a history of fractures.
• Growth and nutrition: assessed regularly, especially around the start of corticosteroid therapy or if swallowing difficulties develop.
• Carrier females: even without symptoms, female carriers of a DMD genetic change face an increased lifetime risk of heart muscle disease and are recommended to begin cardiac screening in late adolescence or early adulthood, with regular follow-up at least every five years starting around age twenty-five to thirty.
Referral to a comprehensive neuromuscular clinic, where neurology, cardiology, pulmonology, orthopedics, physical therapy, and genetic counseling are coordinated, is strongly recommended for every affected individual and family.

[Genetic Counselor]

Duchenne muscular dystrophy is inherited in an X-linked pattern. Because the DMD gene sits on the X chromosome, and males have only one X chromosome, a single altered copy is enough to cause the full condition in a male. Females have two X chromosomes, so a female carrying one altered copy alongside one working copy is usually not significantly affected, though as discussed below some do develop symptoms. In rare instances, a female can have the full, classic DMD picture rather than milder carrier symptoms. This can happen when she has lost or rearranged her second, working X chromosome, when she has inherited an altered copy of the gene from both parents, or when the working copy of the gene happens to be switched off in most of her muscle cells through a process called skewed X-inactivation, in which one of the two X chromosomes in each cell is normally silenced at random but can, in some individuals, be silenced non-randomly in a way that favors the altered copy.

In approximately two-thirds of individuals with DMD who have no other affected family members, the mother is a carrier of the genetic change, even though she has no symptoms herself. In the remaining cases, the genetic change arose new in the affected individual, called a de novo change, and is not present in either parent’s blood cells.
A carrier mother has a fifty percent chance, in each pregnancy, of passing the altered gene copy to a child. A son who inherits it will be affected with DMD. A daughter who inherits it becomes a carrier herself and may, in a minority of cases, develop some degree of muscle weakness or heart involvement of her own. Even when a genetic change appears to be de novo, meaning it cannot be detected in the mother’s blood sample, there remains a fifteen to twenty percent chance that she carries the change in only a portion of her eggs, a situation called germline mosaicism. This means her other children still carry some increased risk of being affected, even when her own testing looks negative.
Because of the implications for future pregnancies and for other family members, molecular testing of the mother, and genetic counseling for the wider family, is recommended once a genetic change is identified in an affected individual. Once the specific family variant is known, prenatal testing and preimplantation genetic testing become available for future pregnancies.

[Genetic Counselor]

Duchenne muscular dystrophy typically becomes noticeable in early childhood, well before a formal diagnosis is made, since the muscle weakness at first can be subtle and easily mistaken for ordinary clumsiness.
• Motor delay: individuals with DMD are often later than average to walk independently, with an average age of about eighteen months compared to closer to twelve months in unaffected children.
• Gait and mobility: a waddling, proximal pattern of weakness produces persistent toe-walking, a rolling gait, and difficulty running, jumping, climbing stairs, or rising from a squat.
• Gower maneuver: because the muscles around the hips and thighs are especially affected, individuals characteristically use their hands to walk up their own legs when rising from the floor, a distinctive sign doctors look for.
• Calf hypertrophy: the calf muscles often appear enlarged and unusually firm, a finding called pseudohypertrophy, caused by fat and connective tissue replacing muscle fibers rather than true muscle growth.
• Cognitive and behavioral features: dystrophin is also present in the brain, and some individuals with DMD have a degree of intellectual disability, learning disability, attention-deficit/hyperactivity disorder, or autism spectrum features, none of which worsen over time the way the muscle disease does.
• Cardiac involvement: the heart muscle is affected as well, though it usually causes no symptoms in early childhood and becomes more evident in the teenage years.

The average age at diagnosis, when there is no known family history to prompt earlier testing, is around four to five years old. A blood test measuring an enzyme called creatine phosphokinase, or CPK, is usually the first step, since CPK levels are dramatically elevated, generally more than ten times normal, in essentially all individuals with DMD. A markedly elevated CPK level in an individual with the characteristic pattern of weakness is followed by genetic testing of the DMD gene, most often starting with testing designed to detect missing or duplicated exons, since this accounts for the large majority of genetic changes, followed by more detailed sequencing if that initial testing does not identify a cause. A muscle biopsy, once the standard diagnostic tool, is now needed only rarely, mainly when genetic testing is inconclusive.

[Genetic Counselor]

Duchenne muscular dystrophy, usually shortened to DMD, sits at the severe end of a group of related conditions called the dystrophinopathies, a spectrum of muscle disease that ranges from an isolated blood marker of muscle breakdown with no other symptoms, all the way through Becker muscular dystrophy, DMD, and a form that mainly affects the heart, known as DMD-associated dilated cardiomyopathy. All of these conditions are caused by changes, called pathogenic variants, in a single gene, DMD, which sits on the X chromosome and is one of the largest genes in the human genome. It provides instructions for a protein called dystrophin, which sits just beneath the outer membrane of muscle cells and links the internal skeleton of the cell to structural proteins outside it, stabilizing the membrane during the repeated stretching and contracting of muscle activity.

Whether a genetic change in DMD produces the severe Duchenne phenotype or the milder Becker phenotype generally comes down to whether the change disrupts what is called the reading frame, the sequence in which genetic instructions are read three letters at a time to build a protein. Changes that throw off the reading frame usually prevent any usable dystrophin from being made at all, leading to the more severe, rapidly progressive Duchenne presentation. Changes that preserve the reading frame usually still allow a shortened but partially working dystrophin protein to be produced, which generally leads to the later-onset, more slowly progressive Becker presentation. This general pattern, called the reading frame rule, predicts the phenotype correctly in the large majority of cases, though exceptions occur, so genetic findings are always interpreted together with the clinical picture.

Because the gene lies on the X chromosome, the condition follows an X-linked pattern, and it is males, who carry only one X chromosome, who are almost always affected with the full clinical picture. About two-thirds of pathogenic changes in the gene are deletions removing one or more of its many building blocks, called exons, with smaller genetic changes and duplications accounting for the remainder.

[Genetic Counselor]

The long-term outlook for Alagille syndrome varies widely and depends heavily on the severity of liver and heart involvement in each individual, which is why lifelong, regular follow-up with a multidisciplinary care team is important. Overall, published data indicate a mortality rate of about eight and a half percent, with most deaths occurring within the first five years of life and most often related to complications of liver transplantation, severe congenital heart disease, severe liver disease itself, or bleeding inside the skull from a blood vessel abnormality. For children whose total bilirubin level, a marker of bile flow, falls below five milligrams per decilitres between six and twelve months of age, the chance of living long-term with their own native liver is notably better, which is one reason early diagnosis and monitoring matter.

Because new complications can appear or evolve over time, ongoing surveillance is recommended across every affected organ system:
• Liver: regular blood tests of liver function, plus alpha-fetoprotein blood testing and liver ultrasound roughly every six months at every age, since people with Alagille syndrome, whether caused by JAG1 or NOTCH2, carry an increased lifetime risk of liver cancer even when other liver findings are mild.
• Growth and nutrition: assessed at every visit.
• Heart and blood vessels: followed by a cardiologist, with brain and blood vessel imaging pursued promptly if any neurological symptoms develop, given the risk of bleeding inside the skull.
• Kidneys: blood pressure checked at every visit, with more detailed blood testing every six to twelve months.
• Development: progress, and specifically attention and planning skills, assessed at least once yearly since these difficulties are increasingly recognized as part of the condition.
• Eyes: periodic examinations, as some individuals develop changes in the retina beyond the classic eye finding seen at diagnosis.
• Skeleton: checked for fracture risk at each visit.

[Genetic Counselor]

Since Alagille syndrome affects several organ systems at once, care is best coordinated by a team that typically includes a clinical geneticist along with specialists in liver disease, heart disease, nutrition, kidney disease, and eye disease, with an organ transplant specialist involved when needed.

Liver-related symptoms, particularly intense itching and impaired bile flow, are usually the most limiting day-to-day problem, and management here has changed meaningfully in recent years:
• Ileal bile acid transporter inhibitors — maralixibat (approved for children older than three months) and odevixibat (approved for children older than twelve months) — have received approval from the United States regulatory health authority specifically for the impaired bile flow of Alagille syndrome. Both work by increasing the amount of bile acid removed through the stool rather than reabsorbed into the body, which can meaningfully reduce itching and is associated with improved event-free survival with the person’s own liver.
• Other medications for itching and fatty skin deposits include ursodeoxycholic acid, cholestyramine, rifampin, and naltrexone.
• Biliary diversion, a surgical procedure to divert bile away from the intestine, is sometimes used when medications are not enough.
• Liver transplantation may be needed when liver disease cannot be adequately controlled. Roughly half of individuals with a history of newborn impaired bile flow eventually require a transplant by adulthood, most commonly within the first five years of life, and survival after transplant is favourable, at about eighty-eight percent by twenty years of age.

Other aspects of care include:
• Correcting deficiencies of the fat-soluble vitamins A, D, E, and K, which are poorly absorbed when bile flow is reduced.
• Optimizing calorie intake, sometimes with a feeding tube, to support growth
• Treatment of congenital heart defects by a cardiologist, which may include a catheter-based procedure or surgery depending on severity.
• Monitoring and management of kidney, skeletal, and developmental concerns as they arise.
• Avoiding contact sports for individuals with significant liver or spleen enlargement, because of injury risk, and avoiding alcohol for anyone with liver disease.

Each individual with Alagille syndrome presents the condition differently, symptoms observed in one may not manifest in others. Each individual with Alagille syndrome is advised to get a detailed evaluation to schedule a treatment plan tailored to them.

[Genetic Counselor]

Alagille syndrome follows an autosomal dominant pattern of inheritance, meaning that a change in just one of the two copies of either JAG1 or NOTCH2 that a person carries are enough to cause the condition; it does not require changes on both copies.

• In roughly sixty percent of individuals, the causative genetic change arose new in that person and was not inherited from either parent, a situation described as a de novo change.
• In the remaining approximately forty percent, the change was inherited from a parent who also carries it.
• Around ninety-six percent of people with a JAG1 change show at least some recognizable feature of Alagille syndrome, a measure called penetrance, though the feature may be as subtle as a heart murmur or a particular eye finding. Because of this, both parents of a newly diagnosed child should be carefully examined by a specialist, and ideally undergo genetic testing themselves, before either is told they do not carry the change.
• For an individual who has Alagille syndrome from any cause, each of their future children has a fifty percent chance of inheriting the same genetic change, although the severity in that child cannot be predicted in advance, even within the same family.
• In about eight percent of families, a parent who appears unaffected and tests negative on a blood sample may still carry the genetic change in only a portion of their reproductive cells, a situation called germline mosaicism. This means the chance of the condition recurring in future children is not zero even when parental testing looks reassuring.

Referral for genetic counseling is recommended so that risk can be assessed accurately for each specific family.

[Genetic Counselor]

Because Alagille syndrome can affect many organ systems, and because severity differs enormously from person to person, doctors rely on a set of five characteristic features to make and confirm a diagnosis rather than looking for one single defining sign.
• Hepatic: a reduced number of small bile ducts within the liver combined with impaired bile flow, known as cholestasis, seen on liver biopsy in about ninety-five percent of affected individuals.
• Cardiac: congenital heart defects, most commonly narrowing of the peripheral pulmonary arteries, found in roughly ninety to ninety-seven percent.
• Skeletal: butterfly-shaped vertebrae in the spine, usually in the chest region, seen on an x-ray in a wide range of thirty-three to ninety-three percent of individuals.
• Ophthalmologic: a distinctive ring-shaped structure at the front of the eye called posterior embryotoxon, present in seventy-eight to eighty-nine percent and usually only found on a careful eye examination.
• Facial: characteristic features including a broad forehead, deep-set eyes, a straight nose with a bulbous tip, and a pointed chin.

Beyond these five defining features, many individuals also have additional findings:
• Kidney abnormalities, in about thirty-nine percent
• Blood vessel abnormalities, including a risk of bleeding inside the skull, in fifteen to thirty percent.
• Poor growth, affecting fifty to ninety percent.
• Developmental delay or difficulty with attention and planning skills.
• An enlarged spleen.
• Intense itching, in about seventy-four percent of children, and fatty skin deposits called xanthomas, in about twenty-four percent, both related to the buildup of bile acids in the skin.

A clinical diagnosis is made when a person has bile duct reduction on liver biopsy together with at least three of the other four major features, or when a person has only one major feature but has a parent or sibling already confirmed to have Alagille syndrome. Because clinical findings can be subtle or absent in infancy, genetic testing of the JAG1 and NOTCH2 genes is used to confirm the diagnosis, most often through sequence analysis of JAG1 first, followed by deletion or duplication testing, and NOTCH2 testing if suspicion remains high after JAG1 testing is negative.

Each individual with Alagille syndrome presents the condition differently, symptoms observed in one may not manifest in others.

[Genetic Counselor]

Alagille syndrome is a multisystem genetic disorder that can affect the liver, heart, skeleton, eyes, face, kidneys, and blood vessels, with a wide range of severity. Some family members carrying the same genetic change have only mild, barely noticeable features, while others develop serious, even life-threatening complications. The condition is caused by changes, known as pathogenic variants, in one of two genes that both take part in a cell communication pathway called the Notch signaling pathway, which guides how the bile ducts, heart, and other organs form correctly before and after birth. In both genes, the disorder arises because one of the two copies a person carries is not working properly, a mechanism called haploinsufficiency, meaning a single working copy is not enough on its own to guide normal organ development.

• JAG1, located on chromosome 20, accounts for approximately ninety-four percent of cases. It provides instructions for a protein called Jagged-1, which signals to Notch receptors on neighboring cells during development. Most JAG1 changes are loss-of-function changes, in which the protein is not made at all or cannot function once made.
• NOTCH2, located on chromosome 1, accounts for approximately two and a half percent of cases. It provides instructions for one of the receptor proteins that Jagged-1 binds to. NOTCH2 changes are more often changes that alter a single building block of the protein rather than eliminating it entirely.

A small proportion of people who show clear features of Alagille syndrome do not have an identifiable change in either gene on current testing, which suggests that other, not-yet-identified genes or mechanisms may occasionally be involved and that testing technology continues to evolve.

[Genetic Counselor]

A short guidance post to keep this board reliable.

1. Always check CTRI (ctri.nic.in) for the registration number before treating any trial as legitimate – search by disease name or sponsor.
2. Genetic report first – most exon-skipping trials require your child’s exact deletion/mutation confirmed by NGS or MLPA testing before you can even ask about eligibility.
3. Contact the trial site directly – use the investigator/sponsor contact info posted in the trial threads, not third-party agents.
4. Be wary of unregistered “treatments” – if a clinic offers a DMD gene therapy or stem-cell treatment with no CTRI number, treat it as unverified and ask fellow members before proceeding.

If there’s any additional queries, please post them in the forum

[Genetic Counselor]

For families looking for support beyond trial participation:

ORD India (Organization for Rare Diseases India) — primary patient advocacy body for DMD in India.
Helpline: +91 8892 555 000 | Email: contactus@ordindia.in
Runs Rare Disease Care and Cure Centers (RDCCC) in Bengaluru & Mysore (Karnataka), plus Kerala, Tamil Nadu, Telangana, and Delhi (including AIIMS partnership).
Offers an E-Library (“Rare Info Series,” neuromuscular disorder sessions), DMD patient leaflets, webinars, and a patient-story section.
DART India (Bengaluru) — beyond running the ASO trial above, also provides counseling, medical advisory, and rehabilitation support independent of trial enrollment.

References:

ORD India — DMD page, https://ordindia.in/diseases/duchenne-muscular-dystrophy-dmd/
DART India, https://www.karnataka.com/ngos/dart-dystrophy-annihilation-research-trust/

[Author]

Posts